Resources
-
Clinical Development of COVID-19 Vaccines
Speaker Presentation Krause Philip, CBER, FDA, 2021
-
Global Comparability/Characterization Strategy for NVX-CoV2373
Speaker Presentation Schenerman Mark, Novavax Inc., 2021
-
Overview of Cross-company (Trade Associations) Discussion on CMC Approaches to Support Development and Supply of COVID Vaccines
Speaker Presentation Campa Cristiana, GlaxoSmithKline, 2021
-
Engineering Cell Lines for AAV Cell-based Potency Assays
Speaker Presentation Whipple Stephanie, Genzyme, a Sanofi Company, 2021
-
Bioassays as Part of an Integrated Control Strategy
Speaker Presentation Van der Plas Martijin, Medical Evaluations Board (MEB), 2021
-
Bioassay Evolution – Where Are We Now?
Speaker Presentation Mire-Sluis Anthony, AstraZeneca, 2021
-
Potency Assays for Engineered Cell Therapies
Speaker Presentation Lowe Emily, Kite, a Gilead Company, 2021
-
The Power of Proper System Suitability Tests - A Case Study of cGMP Method Improvement
Speaker Presentation Li Ruojia, Bristol-Myers Squibb Company, 2021
-
Development of a New Cell Adhesion Bioassay Format
Speaker Presentation Kröner Frieder, Novartis Pharma KG, 2021
-
Potency Assay Strategy for a Fixed-Dose Combination Product
Speaker Presentation Avenal Cécile, F. Hoffmann - La Roche AG, 2021
-
Enhancing the Speed of Vaccine Development by Utilizing Fullt Automated High Throughput Cell Potency Assays
Speaker Presentation Acevedo-Skrip Jillian, Merck & Co. Inc., 2021
-
PMDA Perspective: Recent Trends in the Regulation of Biopharmaceuticals
Speaker Presentation Honda Futaba, Pharmaceuticals and Medical Devices Agency (PMDA), 2020
-
Communications, Regulatory Flexibilities and Quality Challenges for Biologics in the COVID19 Pandemic: An EMA Perspective
Speaker Presentation Shivji Ragini, European Medicines Agency, 2020
-
Regulatory Challenges: Expediting CMC Development While Ensuring Product Quality
Speaker Presentation Levis Robin, CBER, FDA, 2020
-
Regulatory Approaches to CMC Development During COVID-19: Challenges and Opportunities
Speaker Presentation Shapiro Marjorie, CDER, FDA, 2020
-
ICH Q12 Update and Reflections on the USFDA Established Conditions Pilot Program
Speaker Presentation Welch Joel, CDER, FDA, 2020
-
Case Study: Industry Experience from PACMP Pilot Program in Japan
Speaker Presentation Kubodera Yoshinori, Chugai Pharmaceutical Co., Ltd., 2020
-
Introduction of post-approval change management protocol (PACMP) mock-up in Japan preparation
Speaker Presentation Funato Keiko, GlaxoSmithKline K.K., 2020
-
Update of Q12 Implementation in Japan - Japan
Speaker Presentation Yagi Satomi, Pharmaceuticals and Medical Devices Agency (PMDA), 2020
-
Medical Products Agency and the biotech arena in Sweden
Speaker Presentation Welin Mats Barbu Andreea, Andreea Barbu, Swedish Medical Products Agency, 2020